News | May 21, 2025
Marksans Pharma FY25 PAT up 21% at Rs. 382.6 Cr
Q4 FY25 PAT stood at Rs. 90.7 crore as compared to Rs.77.6 crore in Q4 FY24
Q4 FY25 PAT stood at Rs. 90.7 crore as compared to Rs.77.6 crore in Q4 FY24
This global affiliation marks a critical step in the company’s mission to create long-term value through ethical practices, scientific innovation, and inclusive healthcare delivery
EBITDA for the period rose by 23.2% to Rs. 3,797 million
The company has posted net profit of Rs. 485.62 crores for the Financial Year ended March 31, 2025
In Q4 FY25, our pharmaceutical business reported revenue growth of 20% to Rs 351 crore and EBIT growth of 65% to Rs 55 croe, on QoQ basis
Shilpa Pharma Lifesciences, Unit-1, received EIR from USFDA
IOL Chemicals and Pharmaceuticals has posted net profit of Rs.101.07 crores for the Financial Year ended March 31, 2025
Net Profit increased by 15% to Rs. 146 crores in Q4 FY25 and 19% to Rs. 660 crores in FY25
The CDMO upgrade represents a transformational step for Remedium Lifecare
The company has posted net profit of Rs. 91.13 crores for the Financial Year ended March 31, 2025
Subscribe To Our Newsletter & Stay Updated
